Design Therapeutics Reports Q2 2026 Results, RESTORE-FA Modifications, and Pipeline Progress
DSGN has more than doubled off its 52-week low of $3.76.
Summary
Design Therapeutics posted Q2 2026 results with $207.4M in cash and outlined key clinical updates, including RESTORE-FA trial modifications and the start of DT-818 dosing in DM1 patients.
Key Events · Earnings and Guidance · DSGN
-
Q2 2026 Financial Results
Net loss of $20.2 million on R&D expenses of $16.4 million and G&A of $5.8 million. Cash, cash equivalents, and investments totaled $207.4 million as of June 30, 2026.
-
RESTORE-FA Trial Modifications
Trial modified to evaluate 1 mpk as the go-forward dose in a 10-patient, 12-week cohort. Primary endpoint changed to endogenous blood FXN protein percent change from baseline. A dose above 1 mpk is also being explored.
-
DT-818 Phase 1 Initiation
Dosing initiated in a Phase 1 multiple-ascending dose trial of DT-818 for myotonic dystrophy type 1, with data expected in 2027.
-
DT-168 Data Delay
Phase 2 biomarker trial data for DT-168 in Fuchs endothelial corneal dystrophy delayed to 2027 due to a supply issue with blow-fill-seal eye droppers.
Analysis · DSGN · Life Sciences
Design Therapeutics reported Q2 2026 financials with a net loss of $20.2 million and a strong cash position of $207.4 million, providing runway well beyond 12 months. The company announced modifications to its pivotal RESTORE-FA trial for Friedreich ataxia, including a go-forward dose of 1 mpk and a 12-week cohort, with data expected in Q1 2027. Dosing has also begun in a Phase 1 trial for DT-818 in myotonic dystrophy type 1. These updates follow positive four-week data in May and signal continued execution across its GeneTAC platform, though the DT-168 delay due to a supply issue is a minor setback.
At the time of this filing, DSGN was trading at $12.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.7M. The 52-week trading range was $3.76 to $17.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.